Aldeyra Therapeutics Announces 2018 Research Day

Wednesday, June 20, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company

devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research Day to provide an update on current early-stage research programs.  The day will include
presentations from members of the management team focusing on development plans for novel product candidates in systemic inflammatory disease, retinal disease, and cancer.

Management presentations will begin at 9:00 a.m. Eastern Time on Tuesday, June 26, 2018, at the offices of Dechert, LLP in New York City.

A live webcast of the presentation and slide deck will be available via the Company's Investor Relations website at http://ir.aldeyra.com.  Following the live webcast, an archived version will be available on the website until June 25, 2019.

About Aldeyra TherapeuticsAldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune and metabolic diseases. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Corporate Contact:David McMullinAldeyra Therapeutics, Inc.Tel: +1 781-761-4904 ext. 218 dmcmullin@aldeyra.com

Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843Chris.brinzey@westwicke.com

Media Contact:Cammy Duong MacDougall Biomedical Communications 781-591-3443cduong@macbiocom.com

Cision View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-2018-research-day-300669225.html

SOURCE Aldeyra Therapeutics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store